Aditxt, Inc. (ADTX) is a Biotechnology company in the Healthcare sector, currently trading at $0.42. It has a SharesGrow Score of 36/100, indicating a weak investment profile with 2 out of 7 criteria passed.
Analyst consensus target is ADTX = $160 (+37895.7% upside).
Valuation: ADTX trades at a trailing Price-to-Earnings (P/E) of -0 (S&P 500 average ~25).
Financials: revenue is $3M, +724.8%/yr average growth. Net income is $43.1B (loss), growing at -41683.7%/yr. Net profit margin is -1349028.2% (negative). Gross margin is 8.4% (-9.5 pp trend).
Balance sheet: total debt is $3.0B against $5.6B equity (Debt-to-Equity (D/E) ratio 0.54, moderate). Current ratio is 0.31 (tight liquidity). Debt-to-assets is 18.2%. Total assets: $16.5B.
Analyst outlook: 1 / 2 analysts rate ADTX as buy (50%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 17/100 (Fail), Moat 0/100 (Fail), Future 64/100 (Pass), Income 10/100 (Fail).
